/**** START COMMENTS CONFIG ***
vim: tabstop=4;
** The code below must be on the VERY TOP of the page. // more includes on lines 50 and 60
*/
session_start();
ini_set('output_buffering', 1);
include_once("inc.comments_config.php");
//include_once("inc.db.php");
include_once('/www/code_snippets/page_comments/process_comment_submit.php');
// *** END OF COMMENTS CONFIG ***
?>

Call NOW ! Help is available

24 hours a day  7 days a week

1-800-734-6130

Gadolinium Claims Lawyer Attorney for Side Effects

Gadolinium Class Action Lawsuit & Settlements

Gadolinium poisoning:

If
you or someone you know is suffering from gadolinium poisoning,
you must consult our lawyers and attorneys
immediately. There may be a Gadolinium Class Action lawsuit with compensation from a cash settlement. We are currently investigating the
alleged causal link between gadolinium and NFD, although
there is no direct evidence as of yet that establishes
a secure connection. Our vast experience with defective
drugs enables us to move quickly and get you
the justice you deserve.

Nephrogenic Systemic Fibrosis (NSF) Linked to Gadolinium Based Dye Used in Patients

Of the most recently reported Nephrogenic Systemic Fibrosis NSF cases is a 38 year old woman named Sarah Francella who resides in Santa Barbara, CA. Francella, who has been suffering from NSF since an MRI 2 years ago, is enduring the immobilizing aftermath of Gadolinium. With very little research and information available regarding nephrogenic systemic fibrosis this is an uphill battle for many that has just begun and likely won’t be ending soon.

Over a 1,000 cases of Nephrogenic Systemic Fibrosis (NSF) are being investigated nationwide. With growing concern regarding Gadolinium use, a contrast agent used during Magnetic Resonance Imaging (MRI), NSF is making its way to the forefront of both patient and physician concern. Though rare, NSF is a severely painful and sometimes fatal disease that has no known cure. Most common in patients with prior kidney problems, NSF develops 2-3 months following an MRI. Patients who develop this condition experience calcification and hardening beneath the skin. This damage is irreversible, as well as extremely uncomfortable.Questions remain whether or not this is truly a safe compound or not. There have been reported cases of renal (kidney) problems in some patients. The problem seems to occur with patients with renal failure that have had to undergo dialysis.

Audience: Radiologists, Nephrologists, Dermatologists, other healthcare professionalsManufacturers of Gadolinium-based contrast agents issued a Dear Healthcare Professional letter to inform healthcare professionals of the addition of a BOXED WARNING and revisions to the WARNING section of the prescribing information for Gadolinium-based contrast agents as listed above used in Magnetic Resonance Imaging (MRI).

Gadolinium is a clear, non-radioactive liquid approved by the FDA as
an injectible contrast agent used during magnetic resonance
imaging tests (MRI). These advanced tests use high-powered radio
waves to look inside the body, and doctors use Gadolinium to provide better
contrast between healthy and unhealthy tissues.

When Gadolinium fluid is injected
into the veins it is absorbed by the unhealthy tissue, and these areas
appear as very bright compared with the other areas of the body, giving
doctors a clear picture of which organs or areas of the body are abnormal.

The Food and Drug Administration is currently
investigating a connection between gadolinium-based chemical
agents and the disease called Nephrogenic Systemic Fibrosis,
sometimes called Nephrogenic Fibrosing Dermopathy (NFD),
which affects patients suffering from kidney failure. The
FDA believes that a link could exist between NSF and gadolinium
after the Danish Medicines Agency reported 25 cases on
May 29, 2006. Of these cases, 20 were reported in
Denmark and five in Austria. All of these patients
developed NSF within at least three months after contact
with gadolinium.

The symptoms of Nephrogenic Systemic Fibrosis generally include:

Tightening and swelling of the skin, usually in the
extremities

Fibromyalgia type symptoms.

Thickening of the skin around the joints, which restricts
movement

Muscle weakness

Reddened patches on the skin

Skin texture changes one not dissimilar to an orange
peel

Burning, itching, sharp pains in affected areas

Calcification of muscle, skin, tendons

Bone pain in the hips and ribs

Symmetrical skin lesions, commonly on the ankles and
thighs

Yellow plaques near the eyes

Hypertension usually precedes skin lesions

The relatively rapid onset of symptoms combined with the
severity of the condition has baffled doctors, and as such
there is no current successful treatment for NFD.

FDA Boxed Warning for Gadolinium:

FDA notified healthcare professionals of the Agency's request for the addition of a boxed warning and new warnings about the risk of nephrogenic systemic fibrosis (NSF) to the full prescribing information for all gadolinium-based contrast agents (GBCAs). The new prescribing information FDA is requesting highlights and describes the risk for NSF following exposure to a GBCA in patients with acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73 square meters) and patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri-operative liver transplantation period. Healthcare professionals should avoid the use of a GBCA in these patients unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging.

// this code displays comments that have been approved (needs to live in the same directory)
include_once('comments.php');
?>

First Name

Last Name

Phone - -

Email

Address

Zip

Comments

By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.

By leaving this box checked, I agree to receive future advertisements and announcements from our firm, its affiliates and partners.

I agree that submitting this form and the information contained within does not establish an attorney client relationship.

I agree that my information will be reviewed by more than one attorney and/or law firm.

I agree that the information that I will receive in response to the above question is general information and I will not be charged for the response to this e-mail question and I further understand that the law for each state may vary, and therefore, I will not rely upon this information as legal advice. Since this matter may require advice regarding my home state, I agree that local counsel may be contacted for referral of this matter.